Diagnosis and Treatment of Cognitive and Neuropsychiatric Symptoms in Parkinson Disease and Dementia With Lewy Bodies.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic search or meta-analytic pooling.
PubMed 36222767 · doi:10.1212/CON.0000000000001151
What was done
This narrative review summarizes the biological underpinnings, diagnostic criteria, and clinical management approaches for cognitive impairment and neuropsychiatric symptoms (including depression, anxiety, psychosis, impulse control disorders, and apathy) in Parkinson disease (PD) and dementia with Lewy bodies (DLB).
What was found
The abstract provides no quantitative data or effect estimates. It qualitatively describes shared alpha-synuclein neuropathology, overlapping genetic risk, and common clinical manifestations between PD and DLB. The primary clinical distinction highlighted is timing: cognitive impairment precedes or appears within one year of motor symptoms in DLB, whereas in PD it typically emerges more than one year after established motor onset. Management consists of combined pharmacologic and nonpharmacologic strategies aimed at reducing functional disability.
Why it matters
Nonmotor and neuropsychiatric symptoms frequently drive overall disability and caregiver burden in Lewy body spectrum disorders. Differentiating between PD dementia and DLB while recognizing overlapping symptom profiles guides timely, symptom-targeted interventions.
Limits
The abstract reports no original human data, systematic search methodology, or quantitative outcomes. Findings represent broad clinical consensus and pathophysiological summaries rather than empirical trial results.
Cited by
- supports Cognitive impairment is common in Parkinson's disease and is a major contributor to long-term disability.